Aclaris Therapeutics wins Fast Track tag for modzatinib in lichen planus

Aclaris Therapeutics has received Fast Track Designation from the US Food and Drug Administration for modzatinib (ATI-2138) in moderate to severe lichen planus (LP), including oral erosive LP, cutaneous LP, and lichen planopilaris. The Wayne, Pennsylvania-based company said it expects to initiate a phased, multi-part Phase 2b trial of the drug later in the fourth quarter of 2026.

Fast Track status is granted to programmes targeting serious conditions with unmet medical need. It entitles the developer to more frequent FDA interactions during development, and allows for rolling review of the New Drug Application, meaning completed sections can be submitted and reviewed on an ongoing basis rather than as a single package. Fast Track programmes may also become eligible for Priority Review if the relevant criteria are met.

Significance for Aclaris

Lichen planus is a chronic inflammatory condition affecting the skin, mucous membranes, scalp, and nails. Despite its potential to cause significant pain and functional impairment, particularly in its oral erosive form, no therapy has yet been approved by the FDA for any LP subtype. Jesse Hall, Chief Medical Officer at Aclaris, described LP as "a serious, clinically concerning disease with debilitating symptoms that can affect the quality of life of patients suffering from this disorder."

Modzatinib is believed to act via inhibition of interleukin-2-inducible T-cell kinase (ITK) and related kinases, positioning it within the growing class of small-molecule immunokinase modulators targeting T-cell-driven inflammatory pathways. Aclaris has not disclosed full mechanistic detail in this release, but the ITK pathway has attracted increasing attention as a validated target in immune-mediated skin and mucosal diseases.

Market landscape and competitive context

The lichen planus treatment landscape remains largely off-label, with dermatologists and oral medicine specialists relying on corticosteroids, calcineurin inhibitors, and systemic immunosuppressants. The absence of any approved agent creates genuine regulatory and commercial headroom for a first-mover.

The broader immuno-dermatology space is competitive, with Janus kinase (JAK) inhibitors already approved in atopic dermatitis and alopecia areata raising the bar for efficacy benchmarks in immune-mediated skin conditions. Aclaris will need to demonstrate a differentiated safety and efficacy profile as the field matures, particularly given that oral LP carries a small but acknowledged risk of malignant transformation, adding complexity to long-term safety monitoring requirements.

Several academic centres and smaller biotechs have explored biologics and small molecules in LP, but no programme has yet reached late-stage registration trials, underscoring the size of the opportunity. The Fast Track designation will be closely watched by dermatology-focused investors as a signal that FDA sees LP as a viable regulatory pathway, potentially encouraging further investment into the indication.

Aclaris is listed on NASDAQ under the ticker ACRS. The company did not disclose trial site locations, patient numbers for the Phase 2b study, or a timeline for data readout in this announcement.